HomeCompareADRE vs ABBV

ADRE vs ABBV: Dividend Comparison 2026

ADRE yields 5.24% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $76.5K in total portfolio value
10 years
ADRE
ADRE
● Live price
5.24%
Share price
$38.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.2K
Annual income
$731.63
Full ADRE calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — ADRE vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADREABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADRE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADRE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADRE
Annual income on $10K today (after 15% tax)
$445.03/yr
After 10yr DRIP, annual income (after tax)
$621.89/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,244.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADRE + ABBV for your $10,000?

ADRE: 50%ABBV: 50%
100% ABBV50/50100% ADRE
Portfolio after 10yr
$66.5K
Annual income
$13,228.68/yr
Blended yield
19.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ADRE
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADRE buys
0
ABBV buys
0
No recent congressional trades found for ADRE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADREABBV
Forward yield5.24%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$28.2K$104.7K
Annual income after 10y$731.63$25,725.73
Total dividends collected$6.3K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ADRE vs ABBV ($10,000, DRIP)

YearADRE PortfolioADRE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,224$523.56$11,559$438.51$335.00ABBV
2$12,558$549.18$13,494$640.86$936.00ABBV
3$14,012$574.29$15,951$945.97$1.9KABBV
4$15,591$598.84$19,152$1,413.89$3.6KABBV
5$17,306$622.76$23,443$2,146.38$6.1KABBV
6$19,163$646.00$29,391$3,321.96$10.2KABBV
7$21,173$668.54$37,948$5,265.87$16.8KABBV
8$23,345$690.34$50,795$8,596.74$27.4KABBV
9$25,691$711.37$71,034$14,549.41$45.3KABBV
10$28,221$731.63$104,715$25,725.73$76.5KABBV

ADRE vs ABBV: Complete Analysis 2026

ADREStock

The index is developed by the Licensor from a universe of Depositary Receipts defined by the S&P/Bank of New York Mellon ADR Index ("S&P/BNY Mellon ADR Composite Index"). The fund normally holds at least 95% of its total assets in Depositary Receipts that comprise the index, and will seek to track the investment results, before fees and expenses, of the index. It is non-diversified.

Full ADRE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ADRE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADRE vs SCHDADRE vs JEPIADRE vs OADRE vs KOADRE vs MAINADRE vs JNJADRE vs MRKADRE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.